Factors | All patients | PD (nā=ā8) | Non-PD (nā=ā21) | p values |
---|---|---|---|---|
Age (years old) (meanāĀ±āS.D.) (range) | 62.4āĀ±ā15.4 (26ā81) | 72.0āĀ±ā6.0 (65ā81) | 58.6āĀ±ā16.5 (26ā81) | 0.035 |
Gender | 0.481 | |||
āMale | 12 (41.4%) | 4 (13.8%) | 8 (27.6%) | Ā |
āFemale | 17 (58.6%) | 4 (13.8%) | 13 (44.9%) | Ā |
Histology | 1.000 | |||
āPapillary | 21 (72.4%) | 6 (20.6%) | 15 (51.7%) | Ā |
āFollicular | 8 (27.6%) | 2 (7.0%) | 6 (20.6%) | Ā |
Serum glucose level (mg/dl) (meanāĀ±āS.D.) (range) | 110.1āĀ±ā26.2 (84ā204) | 115.0āĀ±ā29.9 (84ā204) | 109.1āĀ±ā25.5 (92ā175) | 0.633 |
Number of measurable lesions (maxā=ā5) | 0.104 | |||
āOne | 18 (62.1%) | 4 (13.8%) | 14 (49.3%) | Ā |
āTwo | 6 (20.6%) | 1 (3.4%) | 5 (17.2%) | Ā |
āThree | 4 (13.8%) | 2 (7.0%) | 2 (7.0%) | Ā |
āFour | 1 (3.4%) | 1 (3.4%) | 0 (0%) | Ā |
Position of metastatic lesions | 0.971 | |||
āLung | 18 (39.1%) | 6 (13.0%) | 12 (26.1%) | Ā |
āLymph nodes | 16 (34.8%) | 6 (13.0%) | 10 (21.7%) | Ā |
āBone | 8 (17.4%) | 3 (6.5%) | 5 (11.0%) | Ā |
āLiver | 2 (4.3%) | 0 (0%) | 2 (4.3%) | Ā |
āPeritoneum | 2 (4.3%) | 0 (0%) | 2 (4.3%) | Ā |
Cycle of therapy | Ā | Ā | Ā | 0.630 |
āOne | 17 (58.5%) | 4 (13.8%) | 13 (44.9%) | Ā |
āTwo | 8 (17.4%) | 2 (7.0%) | 6 (20.6%) | Ā |
āThree | 1 (3.4%) | 0 (0%) | 1 (3.4%) | Ā |
āMore than three | 3 (6.5%) | 2 (7.0%) | 1 (3.4%) | Ā |
Activity of RAI (GBq, meanāĀ±āS.D.) (range) | 3.2āĀ±ā1.2 (1.1ā5.6) | 3.4āĀ±ā1.1 (1.1ā5.6) | 3.1āĀ±ā1.2 (1.1ā5.6) | 0.940 |
Total activity of RAI (GBq, meanāĀ±āS.D.) (range) | 23.9āĀ±ā25.2 (1.1ā37.0) | 15.7āĀ±ā17.1 (1.1ā34.0) | 18.2āĀ±ā16.8 (1.1ā37.0) | 0.982 |
Tg before therapy (range) | 1784.2āĀ±ā4975.4 (0ā24,892.4) | 4032.7āĀ±ā8761.9 (4.42ā24,892.4) | 884.8āĀ±ā1978.4 (0ā8610) | 0.709 |
Change of Tg (range) | ā0.3āĀ±ā0.6 (āā1.0ā0.8) | 1.0āĀ±ā0.6 (āā1ā0.8) | ā0.5āĀ±ā0.5 (āā1ā0.4) | 0.042 |
RECIST evaluation after RAI (months) | 10.2āĀ±ā1.7 | 10.8āĀ±ā0.9 | 9.9āĀ±ā1.3 | 1.000 |